Amarin Corporation plc (ADR)  

(Public, NASDAQ:AMRN)   Watch this stock  
Find more results for amrn
-0.01 (-0.62%)
Real-time:   10:13AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.58 - 1.65
52 week 1.36 - 7.98
Open 1.60
Vol / Avg. 79,679.00/2.49M
Mkt cap 274.18M
P/E     -
Div/yield     -
EPS -1.05
Shares 172.44M
Beta 1.29
Inst. own 32%
Feb 27, 2014
Q4 2013 Amarin Corporation PLC Earnings Conference Call
Feb 27, 2014
Q4 2013 Amarin Corporation PLC Earnings Release
Jan 21, 2014
Amarin Corporation PLC Conference Call to Discuss Company Update and the Recent FDA Action
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -152.49% -630.82%
Operating margin -325.43% -691.08%
EBITD margin - -678.95%
Return on average assets -22.63% -59.02%
Return on average equity - -
Employees 185 -
CDP Score - -


2 Pembroke House Upper Pembroke Street 28-32, Dublin 2
+353-1-6699020 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Amarin Corporation plc (Amarin) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company�s product candidate is AMR101, an ultra-pure omega-3 fatty acid. It is developing AMR101 for the treatment of patients with high triglyceride levels, or hypertriglyceridemia. In September 2011, it filed a New Drug Application (NDA), with the United States Food and Drug Administration (FDA). In December 2011, it commenced patient dosing in its cardiovascular outcomes study of AMR101, titled REDUCE-IT (Reduction of Cardiovascular Events with eicosapentanoic acid (EPA) - Intervention Trial).

Officers and directors

Lars G. Ekman M.D., Ph.D. Independent Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
John F. Thero CPA President, Chief Executive Officer, Assistant Secretary, Director
Age: 52
Bio & Compensation  - Reuters
Michael Farrell Principal Financial Officer and Principal Accounting Officer
Bio & Compensation  - Reuters
Stephen B. Ketchum Ph.D. President - Research and Development, Senior Vice President
Age: 48
Bio & Compensation  - Reuters
Joseph T. Kennedy JD Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
Age: 45
Bio & Compensation  - Reuters
Aaron D. Berg Senior Vice President - Marketing and Sales
Bio & Compensation  - Reuters
Paul E. Huff Senior Vice President, Chief Commercial Officer
Age: 53
Bio & Compensation  - Reuters
Stuart D. Sedlack Senior Vice President - Corporate Development
Age: 48
Bio & Compensation  - Reuters
Joseph S. Zakrzewski Director
Age: 51
Bio & Compensation  - Reuters
David M. Stack Independent Director
Age: 62
Bio & Compensation  - Reuters